SCHEMBL3757566

SCHEMBL3757566

O=C(Nc1cc[c]cc1)C(=O)N1CCOCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.54
RAB9A P51151 4/20 0.54
HTT P42858 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
GAA P10253 3/20 0.49
NPC1 O15118 3/20 0.47
MAPT P10636 3/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.47
NPSR1 Q6W5P4 2/20 0.46
HPGD P15428 1/20 0.46
TP53 P04637 1/20 0.44
ESR2 Q92731 1/20 0.44
BLM P54132 1/20 0.44
TSHR P16473 1/20 0.44
MITF O75030 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL750953 0.84 CYP2C9 (0.71) SMN1; SMN2RAB9ACYP2C9CYP2C19GAA
SCHEMBL28733081 0.81 ALDH1A1 (0.58) SMN1; SMN2RAB9AHTTL3MBTL1CYP2C9
SCHEMBL20981278 0.77 SMN1; SMN2 (0.65) SMN1; SMN2RAB9AHTTL3MBTL1GAA
SCHEMBL16345239 0.76 PHGDH (0.49) L3MBTL1CYP2C9CYP2C19GAAKMT2A
SCHEMBL5198772 0.75 SMN1; SMN2 (0.63) SMN1; SMN2RAB9AHTTCYP2C9CYP2C19
SCHEMBL3757565 0.75 SMN1; SMN2 (0.48) SMN1; SMN2RAB9AHTTL3MBTL1CYP2C9
SCHEMBL5522488 0.74 LMNA (0.73) SMN1; SMN2HTTGAANPC1KMT2A
SCHEMBL12140055 0.73 RAB9A (0.78) SMN1; SMN2RAB9AHTTL3MBTL1NPC1
SCHEMBL12139502 0.72 RAB9A (0.57) SMN1; SMN2RAB9AHTTL3MBTL1NPC1
SCHEMBL962893 0.72 LMNA (0.74) SMN1; SMN2RAB9AHTTCYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA SMN1; SMN2 1864/4885RAB9A 713/4885HTT 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.